Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

471
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
471
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

107
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
107
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

51
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
51
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

89
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
89
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

306
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
306
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

112
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2026
Same author

Efficacy of Bacillus clausii as an adjuvant therapy in pathological neonatal unconjugated hyperbilirubinemia in the Nile Delta region of Egypt: a randomized controlled trial.

Journal of tropical pediatrics·2026
Same author

Healthcare Professionals' Perceptions of AI-Assisted Clinical Decision-Making in Jordan: A Qualitative Study of Trust, Accountability, System Readiness, and Professional Practice.

Healthcare (Basel, Switzerland)·2026
Same author

Association between influenza infection and subsequent Parkinson's disease diagnosis: a systematic review and meta-analysis.

Neurodegenerative disease management·2026
Same author

Metformin repurposing in gout: enhancing febuxostat efficacy through anti-inflammatory and metabolic modulation: a randomized controlled double-blind study.

Inflammopharmacology·2026
Same author

Community Pharmacists' Acceptance of Telemedicine-Enabled Medication Dispensing in Jordan: A Mixed-Methods Study of Patient Safety Concerns, Implementation Barriers, and Required Safeguards.

Healthcare (Basel, Switzerland)·2026

Related Experiment Video

Updated: May 15, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Repurposing Atorvastatin, HMGCO-A Reductase Inhibitor, in Patients with Ulcerative Colitis: A Randomized Controlled

Hayam Ali AlRasheed1, Sahar M El-Haggar2, Sahar K Hegazy2,3

  • 1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Addulrahman University, Riyadh 84428, Saudi Arabia.

Journal of Clinical Medicine
|May 14, 2025
PubMed
Summary

Atorvastatin may help ulcerative colitis (UC) patients. This study found atorvastatin significantly reduced disease activity and key biomarkers like zonulin and myeloperoxidase in UC patients compared to placebo.

Keywords:
atorvastatindisease activity indexmyeloperoxidaseulcerative colitiszonulin

More Related Videos

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
06:31

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

918
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.3K

Related Experiment Videos

Last Updated: May 15, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K
Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
06:31

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

918
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.3K

Area of Science:

  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Ulcerative colitis (UC) is a prevalent inflammatory bowel disease affecting millions globally.
  • Clinical evidence for atorvastatin's efficacy in UC is limited, despite preclinical research.
  • UC symptoms include diarrhea, rectal bleeding, abdominal pain, and weight loss.

Purpose of the Study:

  • To evaluate the protective effects of atorvastatin in ulcerative colitis patients.
  • To assess atorvastatin's impact on fecal myeloperoxidase, serum zonulin, and disease activity index (DAI).

Main Methods:

  • A six-month randomized trial involving mild to moderate UC patients.
  • Control group received mesalamine plus placebo; atorvastatin group received mesalamine plus atorvastatin (80 mg daily).
  • Disease severity assessed via DAI; serum zonulin and fecal myeloperoxidase measured pre- and post-treatment.

Main Results:

  • Both groups showed significant reductions in DAI, zonulin, and myeloperoxidase.
  • The atorvastatin group exhibited significantly greater reductions in DAI (p=0.001), zonulin (p=0.04), and myeloperoxidase (p=0.03).
  • Significant correlations found between DAI and zonulin (r=0.4) and myeloperoxidase (r=0.36) in the atorvastatin group.

Conclusions:

  • Atorvastatin co-administration shows potential as an adjunct therapy for ulcerative colitis.
  • The findings suggest atorvastatin may modulate key inflammatory markers in UC.
  • Further research is warranted to confirm atorvastatin's role in UC management.